Paraneoplastic endocrine syndromes.
Solomon
C G
CG
Harvard Medical School, Boston, Massachusetts.
Dluhy
R G
RG
D000172:Acromegaly / Q000188:drug therapy*; D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000616:Aminoglutethimide / Q000627:therapeutic use; D001971:Bromocriptine / Q000627:therapeutic use; D002116:Calcitonin / Q000627:therapeutic use; D003480:Cushing Syndrome / Q000188:drug therapy*; D003981:Diazoxide / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D005440:Fluid Therapy; D006393:Hemangiopericytoma / Q000150:complications; D006801:Humans; D006934:Hypercalcemia / Q000628:therapy*; D006980:Hyperthyroidism / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D007003:Hypoglycemia / Q000628:therapy*; D007177:Inappropriate ADH Syndrome / Q000628:therapy; D007654:Ketoconazole / Q000627:therapeutic use; D015735:Mifepristone / Q000627:therapeutic use; D008901:Mineralocorticoids / Q000378:metabolism; D008939:Mitotane / Q000627:therapeutic use; D015282:Octreotide / Q000627:therapeutic use; D010018:Osteomalacia / Q000209:etiology / Q000628:therapy*; D000077268:Pamidronate; D009384:Paraneoplastic Endocrine Syndromes / Q000145:classification / Q000188:drug therapy*; D010758:Phosphorus / Q000627:therapeutic use; D008926:Plicamycin / Q000627:therapeutic use; D011441:Propylthiouracil / Q000627:therapeutic use; D012462:Saline Solution, Hypertonic / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000150:complications
D004164:Diphosphonates; D004967:Estrogens; D008901:Mineralocorticoids; D012462:Saline Solution, Hypertonic; D000616:Aminoglutethimide; D010758:Phosphorus; D015735:Mifepristone; D001971:Bromocriptine; D013004:Somatostatin; D011441:Propylthiouracil; D008939:Mitotane; D000324:Adrenocorticotropic Hormone; D002116:Calcitonin; D008926:Plicamycin; D003981:Diazoxide; D000077268:Pamidronate; D007654:Ketoconazole; D015282:Octreotide